An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
